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Summary A matched case-control study in a population of urban, non-menopaused women living in Paris
was performed between 1983 and 1985 to investigate the risk of breast cancer (BC) in relation to various
factors with a particular interest in the effect of the use of oral contraceptive (OC) and the existence of cyclical
mastalgia (CM). Two hundred and ten non-menopaused women, less than 45 years old, with newly diagnosed
BC were compared to 210 controls from the same geographic area matched on year of birth, age, education
level and age at first full term pregnancy (FFTP), when justified.
The adjusted Relative Risk of BC (RRa) was significantly increased for a total duration of OC use longer
than 72 months (RR. 2.80; 95% CI 1.56-5.01), as well as the RRa for OC use above 48 months before FFTP
(3.26 95% CI 1.37-7.76) and, to a lesser extent, the RRa for OC use above 48 months after FFTP (2.02 95%
CI 1.07-3.84) respectively. Adjustment was performed on familial history of BC, personal history of Benign
Breast Disease (BBD), age at menarche.
A previous history of cyclical mastalgia was found to be associated with an increased risk of BC. The
significant increase remained after adjustment on the previously mentioned confounding factors and OC use:
RRa 2.12; 95% CI (1.31-3.43).
Under a precise definition related to the hormonal environment, mastalgia appear to be an interesting
marker of breast cell susceptibility, the importance of which can only be validated by prospective studies.
Mastalgia or mastodynia are a frequent complaint in general
practice (Preece et al., 1976; 1978; Fentiman et al., 1986).
Their cumulated incidence rate in women has been estimated
by some authors (Kallner, 1985; Maddox et al., 1989) to be
as high as 45% during the genital life. They are sometimes
considered as part of fibrocystic disease (Sitruk-Ware et al.,
1977; Vorherr et al., 1986), although their evidence and
somatic relevance are frequently denied (Love et al., 1982;
Dupont & Page, 1985).
Several characteristics of mastalgia seem to establish a
relation between their occurrence and breast oestrogen
impact, namely its bilaterality and periodicity in relation with
the menstrual phases, its disappearance after surgical or
chemical castration or after anti-oestrogen therapy like pro-
gestins or tamoxifen, its possible exacerbation or occurrence
under oestrogen or oral contraceptive use.
Hormonal risk factors for breast cancers have been exten-
sively studied in the past 20 years (MacMahon et al., 1973;
Kelsey, 1979; Korenman, 1980; Cowan et al., 1981; Hender-
son et al., 1982; Kelsey & Berkowitz, 1988; Krieger, 1989).
Several authors (MacPherson et al., 1987a; Muir, 1990) have
already pointed out the long delay between the emergence of
the first cancerous clone and the breast cancer diagnosis and
much effort has been put on the characterisation of high risk
populations, and on the delineation of more susceptible
periods like the period starting at menarche and ending at
first full term pregnancy (FFTP).
More recently, Leinster et al. (1987) showed a higher
incidence of high risk mammographic patterns in women
with cyclical mastalgia and speculated about a possible link
with later occurrence of breast cancer.
To investigate the role of cyclical mastalgia as a potential
precocious marker of breast steroid susceptibility in relation
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to breast cancer, we performed a case control study of 210
newly diagnosed breast cancers and 210 age-, year of birth-,
age at FFTP, if any, and socioeconomic status-matched cont-
rols.
Materials and methods
Case and control selection
All women with primary diagnoses of breast cancer between
I January 1983 and 31 December 1985 in Institut Curie,
Paris, were included into the study provided they were white
caucasian, non-menopaused and their breast cancer diagnosis
occurred before their 45th birthday, for the sake of com-
parability with other studies (Pike et al., 1983; Cancer and
Steroid Hormone Study (CASH), 1986; MacPherson et al.,
1987b; Miller et al., 1989; Olsson et al., 1989; Stadel et al.,
1989; UK National Case-Control Study Group, 1989; Clavel
et al., 1991). Institut Curie is one of the major cancer units in
Paris. The date of diagnosis was the date of the first positive
biopsy.
For every case, a control was randomly selected among
white caucasian female patients living in the same geographic
area and enrolled on a voluntary basis in a chronic health
care program. This program consisted in a yearly medical
examination including breast examination. To be eligible, a
control should have a normal breast examination at the time
of interview and no past or present metabolic contra-indic-
ation to oral contraceptive use or oestrogen therapy, like
glycaemic or lipidic or clotting factor abnormalities.
The probability of exposure to exogenous sex hormones
either as oral contraceptive or as medical treatment for mens-
trual disorders is clearly age-dependent. Furthermore the
available exogenous sexual steroids have changed over the
past 30 years. Finally educational level and age at first full
time pregnancy have been shown to be significant risk factors
for breast cancer. Therefore, controls were matched to cases
simultaneously by age, year of birth, educational level and
age at FFTP when appropriate. The absolute difference
between the ages of a pair of matched case and control was
equal or less to 2 years. The same limit was adopted as far as
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age at FFTP was concerned. Educational level was coded
according to the INSEE (National Institute for Statistical
and Economical Studies) classification, i.e. into six categories
(1) below or equal to the 6th grade; (2) Middle School; (3)
9th grade; (4) High School completed; (5) College level; (6)
University level.
All the cases and the controls gave their informed consent
to fill in the questionnaire.
Between 1 January 1983 and 31 December 1985, 573 new
breast cancers were detected in Institut Curie in non meno-
paused women. Among these patients, 210 were less than 45
years old. During the same period of time, 703 premeno-
paused women were recruited into the Chronic Health Care
program and among them, 408 were less than 45 years old.
This control population was sorted according to the BC
cases, i.e. each BC case was associated with a sub-group of
controls matched on age within 2 years, educational level and
age at FFTP within 2 years when appropriate. For each case,
a control was randomly selected inside the corresponding
group thus ensuring a 1:1 matching.
Interview
Each person enrolled into the study was asked a specific
standardised structured questionnaire by an interviewer.
The two interviewers were female medical doctors qualified
in breast pathology. Before the beginning of the study, all the
interviewers were trained for 2 months in managing their
interview and in completing the questionnaire always in the
same manner. The questionnaire had been previously pre-
tested for 1 year by a team composed of one senior clinician
(R.S.W.) and one senior epidemiologist (J.F.) in the breast
clinic of the Department of Reproductive Endocrinology
until we reached an unambiguous questionnaire.
The interview lasted about 20 min and included basic
demographic informations (age, educational level, occupa-
tion, marital status, height and weight), reproductive history
(age at menarche; menstrual experience; pregnancies; medical
history including benign breast disease history), detailed oral
contraceptives use namely before and after FFTP if any,
familial history of breast cancer, history of previous pre-
menstrual mastalgia.
Oral contraceptive uses were elicited by constructing a
monthly calendar of events starting at menarche up to the
time of the interview. Contraceptive use was associated with
marking events like first sexual intercourse, marriage, FFTP.
Information on brand names used was elicited with the aid of
good colour prints of the packaging, showing its front and
back and its content. Oral contraceptives used by the patients
of this study were recorded according to the three following
categories; (1) standard dose oral contraceptives (SDC) con-
taining 50 micrograms (JLg) per pill of ethynil-estradiol (EE);
(2) Low oral dose contraceptives (LDC) containing less than
40 g per pill of EE; (3) continuous microprogestative pill
(P). However, the limited number of patients exposed to the
two last categories did not allow us to take into account this
variable and only global results are presented.
Definition ofcyclical mastalgia
As the concept ofmastalgia is rather controversial, we adopt-
ed very stringent criteria and interviewers were more partic-
ularly trained in this regard. Details of the questions can be
found in appendix. Cyclical mastalgia (CM) was defined as a
bilateral painful breast swelling, lasting for more than 4 days
and up to 3 weeks, always preceding menses and subsiding
during menstruation. This monthly event was noted only if it
persisted for more than 6 months. This definition clearly
discarded non cyclical mastalgia and Tietze's disease and is in
accordance with classification proposed by previous authors
(Preece et al., 1976; Wisbey et al., 1983). This symptom was
recorded separately for various phases of genital life, i.e.
during the period starting at menarche until FFTP, and after
FFTP if the interviewee had already been pregnant, other-
wise until the time of the interview. For each type of OC
used were recorded the age at first use, the total duration of
use, and, when it was relevant, the existence, exact chrono-
logy and duration of breast pain and swelling.
Statisticalanalysis
Comparisons between groups were performed using the
student's t-test for paired and unpaired quantitative data and
chi square test for qualitative data.
We used the multivariate logistic regression methods for
matched case-control studies (Breslow & Day, 1978).
The strategy of performing a 1:1 analysis exposed us to
overmatching as about 20% of cases could be associated with
the same control. Following the recommendations of several
authors (Breslow & Day, 1980; Brookmeyer et al., 1986), we
initially performed a general matched analysis with unequal
strata and unequal cases and controls within each stratum
using a modified version of the Breslow and Day program
(Thalabard et al., 1989). Then we compared the result of this
global analysis with the results of multiple matched analysis
obtained by randomly picking out, for each case, a control
from the group of possible matched control subjects (B.
Falissard, data unpublished). As we did not observe striking
differences between the results from the different analysis on
all studied variables, either before or after adjustment, only
results from a matched 1:1 analysis are shown.
Tables with a summary of the respective counts for cases
and controls in different situation are shown, but should be
interpreted with caution, as they do not take specifically into
account the matched pairs contrary to the calculations of the
RR. Unadjusted and adjusted relative risk according to clas-
sical potential confounding variables (familial history of
breast cancer, age at menarche, previous benign breast
disease) with their corresponding 95% confidence interval
(95% CI) were computed.
Results
A summary of cases and controls is shown in Table I. No
significant differences were found as far as age at menarche,
age at first OC use are concerned. The total durations of OC
use were statistically significant, while the durations of OC
use before or after FFTP did not differ between the two
groups, but corresponded to smaller sample sizes.
The influence of previously published BC risk factors like
familial history of breast cancer, personal history of BBD,
age at menarche is considered in Table II. The observed
adjusted RR for familial history of BC and personal history
of BBD are 2.89 (1.53-5.43) and 5.55 (2.60-11.87) respec-
Table I Summary of cases and controls results expressed as mean
(standard deviation)
Cases mean Controls mean Significance
(s.d.) (s.d.) p
Age (years) 36.9 (4.5) 36.8 (4.5) N.S.
(n = 210) (n = 210)
Menarche (years) 12.7 (1.5) 12.8 (1.5) N.S.
(n = 210) (n = 210)
Age at FFTP 24.7 (4.2) 24.9 (4.5) N.S.
(n= 173) (n= 173)
Age at first OC use 22.8 (3.9) 23.4 (4.2) N.S.
before FFTP (n = 72) (n = 63)
Duration of OC use 19.7 (40.4) 13.2 (29.3) N.S.
before FFTP (n = 72) (n = 63)
(months)
Duration of OC use 33.3 (45.7) 25.5 (41.2) N.S.
after FFTP (n = 125) (n = 109)
(months)
Total duration of 52.9 (53.1) 38.8 (47.6) 0.004
OC use (months) (n = 162) (n = 143)
Thenumbernin brackets indicates thenumberofsubjectsexposed to
the factor. Last column: P-value (two-tailed situation). N.S. corres-
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Table II Analysis of data according to classical risk factors
Cases Controls Unadjusted RR Adjusted RR'
n(%) n (%) (95% CI) (95% CI)
Age at menarche (yr)
<12 44 (21) 41 (20) 1.10 (0.63-1.91) 1.43 (0.80-2.58)
[12-13] 46 (22) 53 (25) 0.89 (0.52-1.51) 0.98 (0.56-1.73)
[13-14] 55 (26) 50 (24) 1.13 (0.62-1.90) 1.08 (0.62-1.90)
[14- 65 (31) 66 (31) 1.00 1.00
Familial history of BC 54 (26) 22 (11) 3.0 (1.68-5.35) 2.89 (1.53-5.43)
Personal history of BBD
No 159 (76) 198 (94) 1.00 1.00
Yes 51 (24) 12 (6) 5.33 (2.58-11.03) 5.55 (2.60-11.87)
Nodular hyperplasia 15b (7) 5 (3) 4.36 (1.28-14.78) 4.53 (1.32-15.55)
Fibrocystic disease 32b (15) 4 (2) 8.74 (3.01-25.37) 9.11 (2.90-28.62)
Others 6b (3) 3 (1) 2.00 (0.50-8.00) 1.59 (0.35-7.17)
Oral contraceptive use
Never 48 (23) 67 (32) 1.00 1.00
1-24 months 41 (20) 53 (25) 1.08 (0.62-1.88) 1.23 (0.68-2.23)
25-72 months 57 (27) 49 (23) 1.62 (0.95-2.77) 2.00 (1.13-3.55)
>72 months 64 (30) 41 (20) 2.18 (1.27-3.74) 2.80 (1.56-5.01)
[<0.01)c
Oral contraceptive use before FFTP
Never 138 (66) 147 (70) 1.00 1.00
1-24 months 15 (7) 19 (9) 0.96 (0.44-2.08) 1.62 (0.65-4.06)
25-48 months 26 (12) 26 (12) 1.08 (0.54-2.14) 1.44 (0.69-3.23)
>48 months 31 (15) 18 (9) 2.19 (1.03-4.69) 3.26 (1.37-7.76)
[<0.05]c
Oral contraceptive use after FFTP
Never 85 (40) 101 (48) 1.00 1.00
1-24 months 48 (23) 50 (24) 1.34 (0.77-2.35) 1.42 (0.75-2.68)
25-48 months 17 (8) 16 (8) 1.26 (0.58-2.73) 1.64 (0.66-4.09)
>48 months 60 (29) 43 (20) 1.92 (1.09-3.37) 2.02 (1.07-3.84)
[<0.05]c
aCovariates of the adjusted model: familial history of BC, personal history of BBD, age at menarche, 3oral
contraceptive use. bCounts do not sum up to 51 as some women could have had more than one type ofBBD. Cp
value for significant trend.
tively and thus statistically different from one at the 5% risk.
The adjusted RR associated with total duration of OC use
reached a significant level when used more than 6 years (72
months). The RRa corresponding to a total duration of OC
use longer than 4 years, respectively before and after FFTP,
reached statistical significance as well. Data related to the
various subclasses of BBD indicate a higher rate of nodular
hyperplasia and fibrocystic disease in the case-group than in
the control-group, thus leading to increased RRa of BC in
relation to these two types of BBD.
Table III summarises data related to cyclical mastalgia.
CM was associated with a 2-fold increase of RR (2.12; 95%
CI 1.31-3.43), with a symptom-duration effect (P<0.0001).
In all three situations considered, i.e. before FFTP, after
FFTP or during OC use, the adjusted RR of BC associated
with mastalgia was significantly higher than unity, ranging
from 2.09 (95% CI 1.04-4.19) to 2.24 (95% CI 1.19-4.24).
The adjusted relative risk of cyclical mastalgia on BC in
the various subgroups of BBD was respectively 2.06 (95% CI
1.28-3.34) in the patients with no previous history of BBD
as compared with 8.27 (95% CI 1.12-61.21) with a previous
history of nodular hyperplasia and/or fibroadenomatosis,
6.52 (95% CI 0.96-44.40) with a previous history of fibro-
cystic disease and 3.33 (95% CI 0.20-55.87) with other BBD.
The limited number of pairs contributing to the determina-
tion of the coefficients in the underlying statistical model
Table III Summary ofthe data corresponding to the symptom cylical mastalgia (CM). The denominator used in
the calculation of the % is 210 with exceptions indicated in brackets
Cases Controls Unadjusted RR Adjusted RR
n(%) n (%) (95% CI) (95% CI)
Cumulated duration of CM (months)
<6 113 (54) 161 (77) 1.00 1.00
6-48 36 (17) 32 (15) 1.54 (0.90-2.62) 1.12 (0.61-2.05)
49-96 16 (8) 6 (3) 3.41 (1.28-9.08) 2.24 (0.77-6.52)
97- 45 (21) 11 (5) 6.46 (2.87-14.53) 5.54 (2.79-13.39)
[o.00OlJb [<O.00Ol]b
Total CM 97 (46) 49 (23) 2.66 (1.72-4.11) 2.12 (1.31-3.43)
CM before FFTP 51 (24) 23 (11) 2.65 (1.50-4.68) 2.24 (1.19-4.24)
CM after FFTP 74 (43) 35 (20) 2.77 (1.69-4.56) 2.19 (1.26-3.81)
(n= 173) (n= 173)
CM while under OC use 34 (21) 16 (11) 2.31 (1.15-4.74) 2.09 (1.04-4.19)
(n= 162) (n= 143)
aCovariates of the adjusted model: familial history of breast cancer, personal history of benign breast disease
(BBD), age at menarche, oral contraceptive use. bp_ value for significant trend.948 G. PLU-BUREAU et al.
explains the large CI. In order to limit the number of
variables incorporated into the model, adjustment was per-
formed here only on the BBD type-coding variables, cyclical
mastalgia and the corresponding interactions. Therefore, cal-
culated numbers cannot be directly compared to the other
adjusted RR shown in Table III. However, the effect of
cyclical mastalgia clearly emerges independently of the per-
sonal history of BBD.
Discussion
In a case-control study concerning 210 cases of newly diag-
nosed BC cases, and 210 age-, year of birth-, FFTP-, educa-
tion-matched controls from the same geographic area, four
factors were found to be associated with the occurrence of
BC, i.e. family history of breast cancer, personal history of
BBD, OC use and cyclical mastalgia. Both a family history of
BC and a personal history of BBD have already been largely
described as BC risk factors (Anderson et al., 1977; Dupont
& Page, 1985; Wang & Fentiman, 1985; Kelsey & Berkowitz,
1988; Dupont et al., 1989). The magnitude of the observed
effects seems to be in agreement with data reported by these
authors.
Initial cohort studies in the seventies and early eighties
could not find any increase in BC occurrence in oral contra-
ceptive users (Trapido, 1981; Kay & Hannaford, 1988;
Vessey et al., 1989; Romieu et al., 1989). More recently,
several authors have brought evidence suggesting a potential
association between long term oral contraceptive use before
FFTP and later occurrence of BC (Paffenberger et al., 1980;
Pike et al., 1981; Meirick et al., 1986; MacPherson et al.,
1987b; Stadel et al., 1989), although these results have been
and are still widely debated (Schlesselman, 1989; Chilvers &
Deacon, 1990). Our data are consistent with those findings as
we could detect a significant increase of the RR in long term
OC users and this tendency was found as well, though atten-
uated, in long term users before FFTP and, to a lesser extent,
in long term users after FFTP. We could not analyse further
on the specific effect of LOC and progestin only pill due to
insufficient data for exclusive users of those specific OC
types. It is noteworthy that the matching design exposed
both cases and controls to the same type of OC compounds
despite the profound changes in OC composition between the
sixties and the eighties.
Cyclical mastalgia as defined in our study was found signi-
ficantly associated with breast cancer, even after adjustment
for the previously mentioned potential confounding factors.
This result is rather astonishing and must be interpreted with
caution considering the subjectivity of this symptom. The
limits of case-control studies have been already largely
addressed (Skegg, 1988) and could account entirely for the
observed results thus forbiding any generalisation. A pos-
sibility of a selection and a recall bias has to be discussed. A
recall bias could account for these results: in their attempt to
give a rational to the origin of their disease, women diag-
nosed with BC are thought to be more likely to report breast
events than normal women (Skegg et al., 1988). Although we
cannot totally dismiss this possibility, our study design and
mode of interview tried to minimise it; (1) by chosing as
interviewers only qualified female medical doctors; (2) by
giving them a specific training in systematically rating breast
symptoms. None of the interviewers were aware of the study
hypothesis and the interviews of cases and controls were
conducted independently. Moreover, our controls were
chosen among women enrolled into a chronic health care
program on a voluntary basis and were not supposed to be
free of breast abnormalities but BC. The absence of the latter
disease in this category of urban women, who are aware of
the frequency of BC, could have on the opposite encourage
them to report minor breast symptoms in order to get a
qualified advice about their personal risk of contracting a
BC. An increase of the BC RR in relation to the duration of
cyclical mastalgia advocates an absence of a strong recall
bias effect.
A selection bias can be minimised on the following argu-
ments: first, the restriction of our control group to patients
exposed to the same environment, with a matching on year
of birth, age at interview, educational level, age at FFTP,
when possible, should have limited major environmental fac-
tors and birth cohort effect (Lund, 1989); second, as personal
history of BBD is known to increase the risk of BC, a higher
number of patients with previous history of BBD among the
cases could account for the effect of cyclical mastalgia. How-
ever, we still observed the effect of cyclical mastalgia after
adjustment on BBD and no significant interaction between
this factor and BBD could be found.
The statistical analysis was carried out on a 1:1 matched
basis thus ensuing equal strata and facilitating analysis. Over-
matching was ruled out by our comparison with the global
analysis and the simulated study.
Experimental and human data associate breast swelling
and pain with exposure to oestrogens. Wisbey et al. (1983)
noticed that cyclical pain usually begins early in genital life,
before the end of the third decade of age and persists for a
long time, sometimes resuming at a time of a major hor-
monal change like pregnancy, but frequently ending only at
the onset of the menopause, suggesting its association with
individual hormonal secretion characteristics. However it is a
clinical evidence in reproductive endocrinology that plasma
oestradiol levels do not totally reflect the hormonal impact at
the target level. The large inter- and intra-individual vari-
ability in the amount of drugs necessary to achieved the same
effect at the target level (induction of the LH pulse when
monitoring the menstrual cycle; relief of post castration or
post menopausal symptoms in oestrogen replacement thera-
pies) could explain the difficulties of studies aiming to dem-
onstrate an excess in oestrogen plasma level, in women with
BC (Wysowski et al., 1987; Krieger, 1989). Boyd et al. (1988)
have shown an association between the fat intake, the choles-
terol plasma level, which is a precursor of the sexual hor-
mones, and the severity of the symptom. Other authors have
suggested the involvement of prolactin (Watt-Boolson, 1981)
or progesterone (Pike et al., 1983), but always pointing out
to an hypersensitivity to the oestrogen environment. In our
definition cyclical mastalgia is an easy and early marker of
breast susceptibility to oestrogen. The present study suggest
its predictive value in addition to other classical risk factors
of BC. We hope that future cohort studies will include and
record accurately this symptom to prove its pertinency.
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APPENDIX
Practical questions asked to the study subjects in order to detect and
characterise a cyclical mastalgia. These questions were separately
recorded for the immediate period preceding the interview and the
other periods of the genital life, as determined by marking events like
puberty, first sexual intercouse, first oral contraceptive use, first
pregnancy and so on.
- Do (did) you experience breast pain or tenderness?
- Is (was) this breast pain or tenderness bilateral?
- Is (was) the symptom isolated or associated with bilateral breast
lumps or nodules?
- Is (was) this breast pain or tenderness associated with an increase
in volume of your breast? To what extent? Do (did) you change
your bra size? Are (were) you forced to sleep on your back? Does
(did) it interfere with your social, professional or private life?
- What is (was) the timing of the symptom: does (did) the symptom
disappear or is (was), at least, relieved the day the menstrualBREAST CANCER, ORAL CONTRACEPTIVES AND CYCLICAL MASTALGIA 949
bleeding starts? If so, how far from next menses does (did) it start
usually? less than 4 days; more than 3 weeks?
- Do (did) you experience this symptom continuously for more than
6 months? When and how it has disappeared?
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